Analyst Price Target is $19.25
▲ +607.72% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Gemini Therapeutics in the last 3 months. The average price target is $19.25, with a high forecast of $25.00 and a low forecast of $11.00. The average price target represents a 607.72% upside from the last price of $2.72.
Current Consensus is
The current consensus among 4 investment analysts is to buy stock in Gemini Therapeutics.
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.